Mita Yoshie, Teishima Jun, Yao Akihisa, Uematsu Riku, Yoshii Takahiko, Hara Takuto, Fujisawa Masato, Nakamura Ichiro
Department of Urology, Kobe City Hospital Organization Kobe City Medical Center West Hospital, 2-4 Ichibancho, Nagata-ku, Kobe, 653-0013 Japan.
Division of Urology, Department of Surgery Related, Kobe University Graduate School of Medicine, Kobe, Japan.
Int Cancer Conf J. 2024 Jan 24;13(2):103-107. doi: 10.1007/s13691-023-00644-4. eCollection 2024 Apr.
Small cell carcinoma (SCC) of the urinary bladder is a rare and highly aggressive subtype of bladder cancer. Most cases are diagnosed at advanced stages, and its therapeutic strategy remains unestablished. Here, we report a case of bladder SCC in which multidisciplinary treatment has resulted in relatively long-term survival. A 68-year-old man presented with gross hematuria. A cystoscopy revealed an invasive bladder tumor. A transurethral resection of bladder tumor (TURBT) was performed, and the pathological diagnosis was SCC. After systemic chemotherapy using etoposide and carboplatin and subsequent TURBT, a radical cystectomy and ileal conduit were performed. Three months postoperatively, the patient had a recurrence in the para-aortic lymph node. Systemic combination chemotherapy with carboplatin plus irinotecan (CBDCA + CPT-11) was administered, followed by amrubicin and an immune checkpoint inhibitor. In addition to this treatment, radiation therapy for the metastatic region led to the reduction of pain and shrinkage of the metastatic lesion. The patient survived for 2 years after the initial diagnosis. Our report indicates that multidisciplinary treatment can be effective for SCC of the bladder, and a therapeutic strategy including the identification of novel biomarkers should be established.
膀胱小细胞癌(SCC)是膀胱癌中一种罕见且侵袭性很强的亚型。大多数病例在晚期才被诊断出来,其治疗策略仍未确立。在此,我们报告一例膀胱SCC病例,多学科治疗使其获得了相对较长时间的生存。一名68岁男性因肉眼血尿就诊。膀胱镜检查发现有浸润性膀胱肿瘤。进行了经尿道膀胱肿瘤切除术(TURBT),病理诊断为SCC。在使用依托泊苷和顺铂进行全身化疗以及随后再次进行TURBT后,实施了根治性膀胱切除术和回肠代膀胱术。术后三个月,患者腹主动脉旁淋巴结复发。给予卡铂联合伊立替康(CBDCA + CPT - 11)进行全身联合化疗,随后使用安罗替尼和一种免疫检查点抑制剂。除了这种治疗外,对转移区域进行放射治疗减轻了疼痛并使转移病灶缩小。患者在初次诊断后存活了2年。我们的报告表明,多学科治疗对膀胱SCC可能有效,应建立包括鉴定新型生物标志物在内的治疗策略。